Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CHMP Adopts Negative Opinion On KYNAMROTM - Quick Facts

Genzyme, a Sanofi company (SNY: Quote), and Isis Pharmaceuticals Inc. (ISIS: Quote), announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a negative opinion for its marketing authorization application for KYNAMROTM for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Genzyme plans to request a re-examination of the CHMP Opinion.

An application for KYNAMRO is currently under review by the U.S. FDA.

Click here to receive FREE breaking news email alerts for Genzyme Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While the Commerce Department released a report on Friday showing a modest increase in new home sales in the U.S. in the month of September, the uptick came from a significantly downwardly revised level in August. Following the rally seen in the previous session, stocks may give back some ground in early trading on Friday. The major index futures are currently pointing to a lower open for the markets, with the Dow futures down by 38 points. The terrorist group known as the Islamic State in Iraq and the Levant (ISIL) is earning about $1 million each day by smuggling oil out of the Middle East, according to the US Treasury Department. Speaking at the Carnegie Endowment for International Peace on Thursday, Under Secretary for Terrorism and Financial Intelligence David Cohen said "ISIL has raised a significant amount of its money - many
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.